Investigating the role of DCAF15 in Acute Myeloid Leukemia
Official title: Assessment of DCAF15 role in Acute Myeloid Leukemia
Funded at University of Pennsylvania · NIH-11130434 · Data updated 2026-11-12
This study is looking at how a protein called DCAF15 affects the growth of Acute Myeloid Leukemia (AML) and hopes to find new ways to treat it, which could help patients understand their cancer better and explore new treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $483,760 |
| NIH project number | 1R01CA292407-01A1 |
| Project ID | NIH-11130434 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia who may benefit from new treatment strategies targeting the ubiquitin pathway.
✕Less likely to help
Patients with other types of leukemia or hematologic malignancies unrelated to the mechanisms being studied may not receive benefit from this research.
What this research studies
This research focuses on understanding how DCAF15, an E3 ligase, influences the progression of Acute Myeloid Leukemia (AML) by regulating the degradation of specific proteins involved in genome organization. By examining the genetic alterations in AML and the role of the ubiquitin pathway, the study aims to uncover new therapeutic targets that could improve treatment outcomes. Patients may benefit from insights into how their cancer develops and potential new treatment options that arise from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that significantly improve survival rates for patients with Acute Myeloid Leukemia.
How similar studies have gone: Previous research has shown promising results in targeting the ubiquitin pathway for cancer treatment, indicating that this approach may lead to significant advancements in AML therapy.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Busino, Luca — University of Pennsylvania
- Study coordinator: Busino, Luca
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.